{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:23:12Z","timestamp":1771489392448,"version":"3.50.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.kint.2020.07.011","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T04:00:57Z","timestamp":1606795257000},"page":"1400-1402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?"],"prefix":"10.1016","volume":"98","author":[{"given":"Michelle N.","family":"Rheault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2020.07.011_bib1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.07.011_bib2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.07.011_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00467-012-2138-4","article-title":"Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative","volume":"28","author":"Kashtan","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2020.07.011_bib4","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.kint.2020.06.038","article-title":"Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome","volume":"98","author":"Yamamura","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.07.011_bib5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.V114649","article-title":"X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males","volume":"11","author":"Jais","year":"2000","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.07.011_bib6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.tips.2019.07.012","article-title":"Alport syndrome therapeutics: ready for prime-time players","volume":"40","author":"Omachi","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.kint.2020.07.011_bib7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.kint.2020.02.029","article-title":"Clinical trial recommendations for potential Alport syndrome therapies","volume":"97","author":"Weinstock","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.07.011_bib8","doi-asserted-by":"crossref","first-page":"1275\u20121286","DOI":"10.1016\/j.kint.2019.12.015","article-title":"A\u00a0multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome","volume":"97","author":"Gross","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.07.011_bib9","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1038\/s41467-020-16605-x","article-title":"Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5","volume":"11","author":"Yamamura","year":"2020","journal-title":"Nat Commun"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820308991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820308991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:56:43Z","timestamp":1758761803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253820308991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0085253820308991"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2020.07.011","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2020.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2020.06.038","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}